ARTHRITIS&RHEUMATISM
Vol.46,No.3,March2002,pp614–624DOI10.1002/art.10141
©2002,AmericanCollegeofRheumatology
TreatmentofRheumatoidArthritisWithAnakinra,aRecombinantHumanInterleukin-1ReceptorAntagonist,
inCombinationWithMethotrexate
ResultsofaTwenty-Four–Week,Multicenter,Randomized,Double-Blind,
Placebo-ControlledTrial
StanleyCohen,1EricHurd,2JohnCush,3MichaelSchiff,4MichaelE.Weinblatt,5
LarryW.Moreland,6JoelKremer,7MorayeB.Bear,8WilliamJ.Rich,8andDorothyMcCabe8
Objective.Toevaluatetheefficacyandsafetyofanakinraincombinationwithmethotrexate(MTX)inpatientswithactiverheumatoidarthritis(RA).
Methods.Patientswithmoderate-to-severeactiveRAwhowerereceivingMTXfor6consecutivemonths,withstabledosesfor>3months(thosewithdiseasedurationof>6monthsbut<12years)wererandomizedinto6groups:placeboor0.04,0.1,0.4,1.0,or2.0mg/kgofanakinraadministeredinasingle,daily,subcutane-ousinjection.TheprimaryefficacyendpointwastheproportionofsubjectswhomettheAmericanCollegeofRheumatology20%improvementcriteria(attainedanACR20response)atweek12.
Results.Atotalof419patientswererandomizedinthestudy.Patientdemographicsanddiseasestatusweresimilarinthe6treatmentgroups.TheACR20responsesatweek12inthe5activetreatmentplusMTXgroupsdemonstratedastatisticallysignificant(P 0.001)dose-responserelationshipcomparedwiththe
SupportedbyagrantfromAmgen,Inc.1
StanleyCohen,MD:St.PaulMedicalCenter,Dallas,Texas;
2
EricHurd,MD:BaylorMedicalCenter,Dallas,Texas;3JohnCush,MD:PresbyterianMedicalCenter,Dallas,Texas;4MichaelSchiff,MD:DenverArthritisClinic,Denver,Colorado;5MichaelE.Wein-blatt,MD:HarvardMedicalSchool,Boston,Massachusetts;6LarryW.Moreland,MD:UniversityofAlabamaatBirmingham;7JoelKremer,MD:AlbanyMedicalCollege,Albany,NewYork;8MorayeB.Bear,MA,MS,WilliamJ.Rich,MS,DorothyMcCabe,PhD:Amgen,Inc.,ThousandOaks,California.
AddresscorrespondenceandreprintrequeststoStanley
Cohen,MD,DepartmentofRheumatology,5939HarryHinesBoule-vard,Suite400,Dallas,TX75235.E-mail:stanleycohen@radiantresearch.com.
SubmittedforpublicationMarch9,2001;acceptedinrevised
formNovember2,2001.
614
ACR20responseintheplaceboplusMTXgroup.TheACR20responserateintheanakinra1.0-mg/kg(46%;P 0.001)and2.0-mg/kg(38%;P 0.007)dosegroupswassignificantlygreaterthanthatintheplacebogroup(19%).TheACR20responsesat24weekswereconsis-tentwiththoseat12weeks.Similarimprovementsinanakinra-treatedsubjectswerenotedinindividualACRcomponents,erythrocytesedimentationrate,onsetofACR20response,sustainabilityofACR20response,andmagnitudeofACRresponse.Anakinrawassafeandwelltolerated.Injectionsitereactionwasthemostfrequentlynotedadverseevent,andthisledtoprematurestudywithdrawalin7%(1.0-mg/kggroup)to10%(2.0-mg/kggroup)ofpatientsreceivinghigherdoses.
Conclusion.Inpatientswithpersistentlyactive
RA,thecombinationofanakinraandMTXwassafeandwelltoleratedandprovidedsignificantlygreaterclinicalbenefitthanMTXalone.
Rheumatoidarthritis(RA)isachronic,progres-sive,systemic,inflammatorydisorderofunknownetiol-ogycharacterizedbysymmetric,erosive,anddisablingpolyarthritisandawidearrayofextraarticularcompli-cations.Asthediseaseprogresses,irreversiblejointdamagemayleadtolossoffunctionandtodeformity.Long-termstudieshavedemonstratedthatsignificantdisabilityoccursin50–70%ofpatientsafter10–15yearsofdisease(1).
Twoofthemostimportantdiscoveriesinthelast
decadeofRAresearchare1)jointdestructionoccursearlyinthecourseofthedisease,and2)cytokinesare
controlled clinical trials, either alone or in combination with methotrexate....This confirmed that anakinra is a well-tolerated treatment in an RA ...
plus methotrexate (MTX) in patients with active ...Anakinra is effective in the treatment of patients...Combination . Drug therapy . Drug tolerance . ...
with arthritis by anakinra in a patient with_...methotrexate 15 mg per week orally was added to...Treatment of 60 Cases ... 暂无评价 4页 2...
treatment with infliximab plus methotrexate in ...Anakinra for rheumatoid arthritis: a sys tematic ...with rituximab in combination with metha trexate. ...
French market: adalimumab, anakinra, etanercept and...factors associated with a biologic DMARD treatment....combination with another drug, it was methotrexate...
Cardiac repair with intr... 6页 10财富值 2011 Stem cell treatment... 暂无...anakinra, abatacept, and rituximab, often in combination with MTX, have be...
methotrexate Start methotrexate ± Combine with ...treatment target is clinical remission or, if ...combination therapy (with or without addtion of ...
treatment strategy in combination with one or more...MAb tocilizumab and the IL-1 inhibitor anakinra....with active RA receiving methotrexate plus either ...
treatment of RA: infliximab, etanercept, adalimumab...(21/23 with methotrexate, 1/23 with ...efficacious at lowering HAQ as combination therapy....
treatment of RA: infliximab, etanercept, adalimumab...(21/23 with methotrexate, 1/23 with ...efficacious at lowering HAQ as combination therapy....
热门文档